(BUSINESS WIRE)–Jan. 12, 2015– Illumina, Inc. (NASDAQ:ILMN) today announced it has expanded the world’s most comprehensive next-generation sequencing (NGS) portfolio with the launch of the HiSeq X Five System and HiSeq 3000/4000 Systems. Over the last five years, the HiSeq Sequencing System family has been established as the platform of choice for high-throughput, production-scale sequencing laboratories. The new… Read more
Shares of Illumina opened today at $195.92 and are currently trading down at $194.32. ILMN has a 1-year high of $199.47 and a 1-year low of $113.15. The stock’s 50-day moving average is $187.99 and it’s 200-day moving average is $177.13.
On the ratings front, Illumina has been the subject of a number of recent research reports. In a report published on January 6, analyst Tycho Peterson from J.P. Morgan assigned a Buy rating to ILMN, with a price target of $270, which represents a potential upside of 37.8% from where the stock is currently trading. Separately, on November 28, Wedbush`s Zarak Khurshid maintained a Buy rating on Illumina shares and has a price target of $200.
In total,2 research analysts have assigned a Hold rating and 3 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $195.92 which is 3.4% above where the stock opened today.
Illumina, Inc., is developer, manufacturer and marketer of integrated systems for the large scale analysis of genetic variation and biological function.